Screener
CytomX Therapeutics CTMX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Research and development | 17,598 | 13,322 | 36,836 | 32,189 |
| General and administrative | 7,601 | 6,622 | 18,294 | 16,050 |
| Total operating expenses | 25,199 | 19,944 | 55,130 | 48,239 |
| Income (loss) from operations | (23,781) | (1,286) | (43,453) | 21,336 |
| Interest income | 3,157 | 1,178 | 4,647 | 2,133 |
| Other income | 18 | 17 | 11 | 28 |
| Income (loss) before income taxes | (20,606) | (91) | (38,795) | 23,497 |
| Provision for income taxes | 60 | 63 | 119 | 126 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's operating income?
- CytomX Therapeutics (CTMX) reported operating income of -$23.78M in Q2 2026.
- How has CytomX Therapeutics's operating income changed year-over-year?
- CytomX Therapeutics's operating income decreased by 1749.2% year-over-year, from -$1.29M to -$23.78M.
- What is the long-term trend for CytomX Therapeutics's operating income?
- Over 4 years (2021 to 2025), CytomX Therapeutics's operating income has grown at a -33.7% compound annual growth rate (CAGR), from -$116.04M to -$22.37M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about CytomX Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude